InvestorsHub Logo
Followers 19
Posts 1991
Boards Moderated 0
Alias Born 02/25/2017

Re: NoMoDo post# 50828

Wednesday, 04/12/2017 8:31:20 AM

Wednesday, April 12, 2017 8:31:20 AM

Post# of 106839
The only logical reasoning for reactivion of the trial is because RMAT designation is coming imo

These trials are very expensive and without RMAT, the FDA knows it would be extremely difficult to continue the trials.

So the FDA wouldn't have them reactivate the trial if they weren't looking positively at RMAT designation possibilities.